Clinical trial
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
NCT02388919
Study timeline
Study start (actual)2015-02-26Date precision: day
Registry last updated2017-09-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Interventions
Sponsors & collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.lead sponsor
Mapped research locations
BeijingBeijing Municipality, China4ShanghaiShanghai Municipality, China4HangzhouZhejiang, China3ChangshaHunan, China2JinanShandong, China2TianjinTianjin Municipality, China2ChongqingChongqing Municipality, China2NanchangJiangxi, China2GuangzhouGuangdong, China1ChengduSichuan, China1ChangchunJilin, China1ShenyangLiaoning, China1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02388919 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.